ArticleOral oncology2010
Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery.
Article in Oral oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 57 citations in OpenAlex.
- The cardiac toxicity of PAMAM dendrimer drug delivery systems can be attenuated with the adjunct use of cardioprotective agents.Biomolecules & biomedicine · 2025Article
- Bioadhesive Hyaluronic Acid/Dopamine Hydrogels for Vascular Applications Prepared by Initiator-Free Crosslinking.International journal of molecular sciences · 2022Article
- Novel G-CSF conjugated anionic globular dendrimer: Preparation and biological activity assessment.Pharmacology research & perspectives · 2021Article
- Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy.International journal of molecular sciences · 2021Review
- Polyamidoamine Dendrimer Grafted with an Acid-Responsive Charge-Reversal Layer for Improved Gene Delivery.Biomacromolecules · 2020Article
- Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference.International journal of pharmaceutics · 2019Article
- Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides.Nucleic acids research · 2018Article
- Development of mannose functionalized dendrimeric nanoparticles for targeted delivery to macrophages: use of this platform to modulate atherosclerosis.Translational research : the journal of laboratory and clinical medicine · 2018Article
- Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to the Transferrin and Epidermal Growth Factor Receptors.Journal of personalized medicine · 2018Article
- Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.Acta biomaterialia · 2017Article
- Folic acid-decorated polyamidoamine dendrimer mediates selective uptake and high expression of genes in head and neck cancer cells.Nanomedicine (London, England) · 2016Article
- Article
- Targeted nanosystems: Advances in targeted dendrimers for cancer therapy.Nanomedicine : nanotechnology, biology, and medicine · 2016Review
- Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery.Drug discovery today · 2015Review
- Click hybridization of immune cells and polyamidoamine dendrimers.Advanced healthcare materials · 2014Article
- Dendrimer advances for the central nervous system delivery of therapeutics.ACS chemical neuroscience · 2014Review
- Electrospun blends of gelatin and gelatin-dendrimer conjugates as a wound-dressing and drug-delivery platform.Biomacromolecules · 2013Article
- Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Dendrimers as carriers for siRNA delivery and gene silencing: a review.TheScientificWorldJournal · 2013Review
- Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for DNA, shRNA and siRNA.Pharmaceutics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
We designed an epidermal growth factor (EGF)-containing polyamidoamine (PAMAM) Generation 4 dendrimer vector labeled with quantum dots for targeted imaging and nucleic acid delivery. (1)H NMR, SDS-PAGE, and Western blotting were applied to characterize the synthesized G4.0-GGG-EGF nanoparticles. Targeting efficiency, cell viability, proliferation, and intracellular signal transduction were evaluated using HN12, NIH3T3, and NIH3T3/EGFR cells. We found that EGF-conjugated dendrimers did not stimulate growth of EGFR-expressing cells at the selected concentration. Consistent with this, minimal stimulation of post-receptor signaling pathways was observed. These nanoparticles can localize within cells that express the EGFR in a receptor-dependent manner, whereas uptake into cells lacking the receptor was low. A well characterized vimentin shRNA (shVIM) and yellow fluorescent protein (YFP) siRNA were used to test the delivery and transfection efficiency of the constructed targeted vector. Significant knockdown of expression was observed, indicating that this vector is useful for introduction of nucleic acids or drugs into cells by a receptor-targeted mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.